Last reviewed · How we verify
TMC114; TMC41629 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TMC114; TMC41629 (TMC114; TMC41629) — Tibotec Pharmaceuticals, Ireland.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TMC114; TMC41629 TARGET | TMC114; TMC41629 | Tibotec Pharmaceuticals, Ireland | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TMC114; TMC41629 CI watch — RSS
- TMC114; TMC41629 CI watch — Atom
- TMC114; TMC41629 CI watch — JSON
- TMC114; TMC41629 alone — RSS
Cite this brief
Drug Landscape (2026). TMC114; TMC41629 — Competitive Intelligence Brief. https://druglandscape.com/ci/tmc114-tmc41629. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing